How about if you can invest right at the very beginning of a mega-profit opportunity in the cannabis sector? – We expect this stock will get us huge profits in this global cannabis boom! The unique patent portfolio, network and visionary management / consulting team makes PIVOT Pharmaceuticals an extremely promising top investment!
Every equity investment in the cannabis sector should fulfill certain criterias:
- Top Management & Branding Experts!
- Enough money in the treasury to execute the strong business plans!
- Pharma Meets Cannabis – Know-how and Vision!
Top Management & Branding Experts!
Our cannabis top pick PIVOT Pharmaceutical was able to recruit branding superstar Joe Mimran to the Advisory Board. Joe Mimran is a world-renowned and extremely successful designer and branding expert. He founded e.g. the fashion label ‘Club Monaco’ that he sold to Ralph Lauren in 1999.
The successful entrepreneur was also a few years ago jury member of the show, Dragons Den ‘. We all know the German TV show ‘Die Höhle der Löwen’ – Dragons Den is the english equivalent! The show offers several entrepreneurs the opportunity to present their diverse business ideas to a jury of five wealthy investors, the “Dragons” of the show’s title, and the pitch for financial investment, in return for offering a share of the business.
We are sure that star entrepreneur Joe Mimran will support greatly the management in branding & advertising of several Cannabis products. The management of PIVOT comes from the pharmaceutical industry and knows very well which high quality any products needs to have.
Enough cash in the treasury to execute the strong business plan!
The best business idea does not work if there is no money in the treasury! This is not the case with our new cannabis pearl: With a recently completed (and significantly oversubscribed!) capital raise over C$ 15 million, PIVOT is well positioned to implement the growth strategy and new product developments!
Pivot intends to operate in three key markets, including the European Union, Canada and California. The goal is to fully exploit the potential of the large portfolio of patented, science-based cannabis products for consumers. The financing of this ambitious project stands, whereby the company clearly distinguishes from other market participants, who often have good ideas but no capital for execution their plans!
Pharma Meets Cannabis – Know-how and Vision!
Pivot Pharmaceuticals Inc. is a cannabis company engaged in the development and commercialization of therapeutic pharmaceuticals and nutritional supplements based primarily on cannabinoid using innovative patented technologies.
Among the advantages of the 15 (!!!) patented technologies, which allow a targeted processing of cannabinoids and their integration into countless products, include, among other things, a higher dosage accuracy, especially for food (so-called ‘edibles’, an emerging multi-billion-dollar market (!), a much faster, cheaper and more accurate manufacturing process, as well as a significant increase in bioavailability!
The potential product pipeline of Pivot includes e.g. Drinks, vegan capsules, soluble tablets, creams and gels, analgesics and powders for the food market.
Source: Company presentation of PIVOT Pharmaceuticals Inc
First revenues expected in 2019 – an initial production order for 100,000 100,000 CBD oil bottles placed. This company is much further ahead than it’s peers!
Significant increase in future sales and new products in preparation!
Do not miss this investment opportunity – this cannabis stock has everything a champion needs.
PIVOT has enough capital to bring visionary ideas & new products to the market. The experienced management is supported by branding experts.
More background information and the detailed corporate introduction on PIVOT Pharmaceuticals can be found here!
Conclusion: Top timing – currently we see an attractive buying opportunity in PIVOT Pharmaceuticals. Early investors who take advantage at this moment may be waving several hundred percent gains. We currently see an extremely high upside potential in the stock. With the recent C$ 15 million capital increase and the appointment of branding superstar Joe Mimran to the Advisory Board, the company is well positioned to capitalize on the coming Cannabis mega-boom!
|Name:||PIVOT Pharmaceuticals Inc.|
|Equity ticker Germany:||NPAT|
|Equity ticker Canada:||PVOT.CN|
|Last stock price as of June 24, 2019:||0,37 C$|
Please note that turnover are generally higher on the Canadian main exchange than on German stock exchanges. In general, limit orders are the preferable option compared to ‘unlimited orders‘.
We are not investment advisors – please be sure to read our legal notes / disclaimer.
Our opinion: PIVOT should be part in in every well-diversified cannabis portfolio!
The contents of the „web pages“, the newsletters and other publications are prepared with the utmost care. Despite all care in the preparation, Financial Research & Publication Ltd assume no liability or responsibility for the correctness, completeness and timeliness of the information contained in the content provided. Furthermore, the relevance of any price forecasts / price targets is not guaranteed in any way whatsoever. The use of the content of the „web pages“, the newsletters and other publications is at the user’s own risk. The web offer is intended for users resident in the Federal Republic of Germany, Switzerland and Austria. The web page is not intended for users who are resident in countries other than those mentioned above, have been or are otherwise subject to the regulations of other countries. Financial Research & Publication Ltd does not assume any liability or guarantee that the information contained in this web page is in accordance with the laws of other states than the Federal Republic of Germany, Switzerland and Austria.
All publications (eg. interviews, articles, short reports, featured company reports, stock market letters, newsletters, sample portfolios, chart-technical assumptions etc.) are for information purposes only and do not constitute trade recommendations regarding the purchase or sale of the instruments discussed. All publications are not to be equated with professional financial analysis but merely reflect the opinion of the website operator (and / or its internal or external editorial staff or business partners). Our produced content has a journalistic nature. The website operator and the authors of all website content assume no responsibility for the topicality, correctness or completeness of the information contained in the publications. The website operator and the external authors are not investment advisors.
The subject of published financial analysis or website content may be shares of companies that have a low market capitalization. Especially for companies with a low market capitalization, investors often have to expect high volatility or low market liquidity.
The subject of the published content on the websites are mostly stocks, that are associated with major price risks and are therefore unsuitable for inexperienced or risk-averse investors. This is especially true for all Over The Counter (OTC), i.e. the so-called outside of a monitored stock exchange or regulated market. The same applies to shares that are traded on the Australian Stock Exchange (ASX), on Canadian stock exchanges (i.e. Toronto or Vancouver) or on the Alternative Investment Market (AIM), a segment of the London Stock Exchange. The shares we analyzed or feature at our web pages are frequently traded on any of these markets in which they are segments of the highest risk category. Instruments which are traded, are threatened at any time by the possibility of a total loss, high volatility and the possibility of reduced liquidity and marketability in particular due to low trading volumes. High price opportunities are faced with enormous risks.
All of the information contained in the „web pages“, the newsletters or other published content neither constitutes a solicitation nor an offer to sell or purchase any investment or for making other transactions. It is also not a recommendation in the context of investment advice.
Any forecasts or opinions expressed reflect our own, subjective and current views of the publisher and are for guidance and information only. The „web pages“ do not consider specific investment objectives, financial situation or particular needs of individual users. The securities and financial instruments presented on these „web pages“ may not be suitable as an investment instrument for every user. Please do your own Due Dilligence.
Financial Research & Publication Ltd assumes no liability for trade ideas, market forecasts and other information made available. This is in no way a call for individual or general reproduction. The background information, trade ideas, market forecasts and securities analyzes by Financial Research & Publication Ltd published on its „web pages“, does not constitute an offer for sale of the listings handled nor a solicitation to buy or sell shares, but also not of commodities, currencies, other securities or structured and derivative financial products. The versions are based on sources the editor believes to be trustworthy.
Although the conclusions and statements contained in the analysis, publications and market assessments have been drawn with reasonable diligence, we assume no responsibility or liability for errors, omissions or incorrect information. This is also true for all of the opinions expressed by our interlocutors in the interviews, figures and expressions. Before a customer makes investment decisions, he should have carefully gathered information about the opportunities and risks of the investment. A positive performance of a financial product in the past can in no way be an indication of a future performance. The reader is urged to check all information and allegations himself. An investment in the featured, sometimes highly speculative shares should not be made without analyzing and reading the latest balance sheets, assets reports and press releases of the company. Material on this website may contain technical or inaccuracies, typographical errors or omissions, for which we assumes no responsibility. Price forecasts for financial instruments in our stock market bulletins and newsletters do not constitute a financial analysis / investment recommendation, they are based purely on subjective technical chart based forecasts of the author.
Disclosure of Interest:
Information pursuant to Section § 34b of the German Securities Trading Act [WpHG] and to Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation)
An individual disclosure regarding securities positions of the publisher and the authors and / or the remuneration of the publisher or the authors by the company or third parties involved in publications are expressly stated in or under the respective publication. This also applies to options and derivatives based on these securities.
The website operator provides companies with marketing and advertising services. We will be compensated for advertising services by these featured companies (sponsors) or by external third parties (e.g. consultants, who have business relationship with the companies). Here is a conflict of interest. Furthermore, a consulting or other service contract may exist or existed between the featured companies promoted on our websites and Financial Research & Publication Ltd, which also constitutes a conflict of interest. Since we can at no time rule out that other media, research provider or stock promotors publish articles or feature our clients during the same period, a symmetrical generation of information and opinion can occur. Nor can it be ruled out that companies that have booked modules to increase market awareness at our websites will not use other service providers in parallel.
We are compensated by featured companies (sponsors) on our website for advertising and maketing services. We are unable to verify all of the data released by public companies or its management. Featured companies are only profiled, we do not recommend stocks to buy or sell. We cannot guarantee all information are accurate and we may make forward looking statements that are uncertain and risky.
Financial Research & Publication Ltd or employees of the Company may at any time conduct buy or sell transactions in the shares of the featured companies (i.e. long or short positions). This also applies to options and derivatives, based on these securities. Those transactions may affect the respective company’s stock price under certain circumstances. Published information on the „web pages“, the newsletters, recommendations, interviews and company presentations are often paid by the respective company or third parties (so-called „third parties“). The „third parties“ include, for example, Investor Relations, Public Relations, Consultants, Brokers and Investors. Financial Research & Publication Ltd may partly directly or indirectly be compensated for the preparation and electronic distribution and other services in cash, and/-or shares / options by the so-called „third party” or direct by featured company. Even if we create each analysis and other content to the best of knowledge and belief and professional standards, we advise you to involve further external sources, such as your local bank or a consultant you trust regarding your investment decisions.
Information and analysis provided is for entertainment, informational and educational purposes only. Nothing in an article, research report, Newsletter, stock report, commentaries interview and other published content constitutes or can be construed as investment advice or an offer or solicitation to buy or sell a stock.
Articles, interviews or other content is based on public information and conversations with Management or company employees. We are unable to verify all of the data released by public companies or its management. Featured companies are only profiled, we do not recommend stocks to buy or sell. We cannot guarantee all information are accurate and reliable. The information may not be complete or correct. We may make forward looking statements that are uncertain and risky.
We require our staff and independent external authors and clients to disclose their positions in individual securities that are mentioned in a publication that they author and that is featured on our website and written content.
IMPORTANT: Although we require our staff and independent external authors and clients to disclose their positions in individual securities that are mentioned in a publication that they author and that is featured on our websites and publications, we cannot and will not guarantee that the information they disclose or fail to disclose is accurate, honest, truthful and complete.
In addition, portions of our websites may contain opinions that are different from other portions of our websites. Our stuff, external authors, clients, advertisers and agents may, from time to time, have long and short positions in, or buy or sell the securities, or derivatives thereof, of companies mentioned in respective website or other published content and may take positions inconsistent with the views expressed in the content.
We may hire third party service providers to electronically disseminate live news and content regarding our clients / our profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer even where such compensation is not disclosed by them.
No guarantee of price data
Financial Research & Publication Ltd does not assume any liability for the accuracy of the charts and data of commodities, currency and equity markets presented in the „web pages“, in the newsletters and all produced content. Displayed prices and data may be time-delayed and out-of-date.
Financial Research & Publication Ltd
20-22 Wenlock Road
London N1 7GU
E-Mail: [email protected]
Responsible person: Paul Miller
Tel. +44 20 3608 1991